SynthesisThe Lancet. Oncology2010
Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies.
Synthesis in The Lancet. Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 340 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
340 citing papers in PubMed, 11 syntheses or guidelines pooled it, 649 citations in OpenAlex.
- Obesity and Risk of Pre- and Postmenopausal Breast Cancer in Africa: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- Acromegaly and breast cancer risk: evidence from a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Risk factors for breast cancer: an umbrella review of observational cohort studies and causal relationship analysis.Frontiers in oncology · 2025Pooled it
- Effectiveness of low-fat diet on the levels of insulin-like growth factor-1 and insulin-like growth factor binding proteins: a systematic review and meta-analysis of randomized controlled clinical trials.Journal of health, population, and nutrition · 2024Pooled it
- Pooled it
- Association of physical weight statuses defined by body mass index (BMI) with molecular subtypes of premenopausal breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2024Pooled it
- Knowledge mapping of metformin use on cancers: a bibliometric analysis (2013-2023).Frontiers in pharmacology · 2024Pooled it
- Does Laterality in Breast Cancer still have the Importance to be Studied? A Meta-analysis of Patients with Breast Cancer.Current medicinal chemistry · 2024Pooled it
- The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies.Nutrients · 2022Pooled it
- The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke.Endocrine · 2017Pooled it
- Serum Insulin-Like Growth Factor Axis and the Risk of Pancreatic Cancer: Systematic Review and Meta-Analysis.Nutrients · 2017Pooled it
- Randomized trial of exercise on cancer-related blood biomarkers and survival in women with ovarian cancer.Cancer medicine · 2023Trial
- Effects of Estradiol/Micronized Progesterone vs. Conjugated Equine Estrogens/Medroxyprogesterone Acetate on Breast Cancer Gene Expression in Healthy Postmenopausal Women.International journal of molecular sciences · 2023Trial
- Green Tea Catechin Extract Supplementation Does Not Influence Circulating Sex Hormones and Insulin-Like Growth Factor Axis Proteins in a Randomized Controlled Trial of Postmenopausal Women at High Risk of Breast Cancer.The Journal of nutrition · 2019Trial
- Trial
- A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer.The Journal of nutrition · 2018Trial
- Adult height and all-cause and cause-specific mortality in the Japan Public Health Center-based Prospective Study (JPHC).PloS one · 2018Trial
- Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.British journal of cancer · 2017Trial
- Associations of breast DNA methylation-based measures of biological ageing with obesity-related breast cancer risk markers.Epigenetics · 2026Article
- The MASLD-Cardio-Oncology Triangle: Dietary Patterns, Metabolic Remodelling and Implications for Cancer Therapy Tolerance.Nutrients · 2026Review
280 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
backgroundInsulin-like growth factor 1 (IGF1) stimulates mitosis and inhibits apoptosis. Some published results have shown an association between circulating IGF1 and breast-cancer risk, but it has been unclear whether this relationship is consistent or whether it is modified by IGF binding protein 3 (IGFBP3), menopausal status, oestrogen receptor status or other factors. The relationship of IGF1 (and IGFBP3) with breast-cancer risk factors is also unclear. The Endogenous Hormones and Breast Cancer Collaborative Group was established to analyse pooled individual data from prospective studies to increase the precision of the estimated associations of endogenous hormones with breast-cancer risk.
methodsIndividual data on prediagnostic IGF1 and IGFBP3 concentrations were obtained from 17 prospective studies in 12 countries. The associations of IGF1 with risk factors for breast cancer in controls were examined by calculating geometric mean concentrations in categories of these factors. The odds ratios (ORs) with 95% CIs of breast cancer associated with increasing IGF1 concentrations were estimated by conditional logistic regression in 4790 cases and 9428 matched controls, with stratification by study, age at baseline, and date of baseline. All statistical tests were two-sided, and a p value of less than 0.05 was considered significant.
findingsIGF1 concentrations, adjusted for age, were positively associated with height and age at first pregnancy, inversely associated with age at menarche and years since menopause, and were higher in moderately overweight women and moderate alcohol consumers than in other women. The OR for breast cancer for women in the highest versus the lowest fifth of IGF1 concentration was 1.28 (95% CI 1.14-1.44; p<0.0001). This association was not altered by adjusting for IGFBP3, and did not vary significantly by menopausal status at blood collection. The ORs for a difference in IGF1 concentration between the highest and lowest fifth were 1.38 (95% CI 1.14-1.68) for oestrogen-receptor-positive tumours and 0.80 (0.57-1.13) for oestrogen-receptor-negative tumours (p for heterogeneity=0.007).
interpretationCirculating IGF1 is positively associated with breast-cancer risk. The association is not substantially modified by IGFBP3, and does not differ markedly by menopausal status, but seems to be confined to oestrogen-receptor-positive tumours.
fundingCancer Research UK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.